Evidence map›Paper›PMID 37388365›Full record

ArticleBioMed research international2023

Bioprospection of Selected Plant Secondary Metabolites as Modulators of the Proteolytic Activity of

Abdulhakeem Olarewaju Sulyman, Oluwapelumi Oluwaseun Aje, Emmanuel Oladipo Ajani, Rukayat Abiola Abdulsalam, Fatai Oladunni Balogun, Saheed Sabiu

Abstract read
In one paragraph

Article in BioMed research international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Abdulhakeem Olarewaju SulymanDepartment of Biochemistry, Faculty of Pure and Applied Sciences, Kwara State University, P.M.B. 1530, Malete, Ilorin, Nigeria.ORCID https://orcid.org/0000-0003-3660-0916
Oluwapelumi Oluwaseun AjeDepartment of Biochemistry, Faculty of Pure and Applied Sciences, Kwara State University, P.M.B. 1530, Malete, Ilorin, Nigeria.
Emmanuel Oladipo AjaniDepartment of Biochemistry, Faculty of Pure and Applied Sciences, Kwara State University, P.M.B. 1530, Malete, Ilorin, Nigeria.
Rukayat Abiola AbdulsalamDepartment of Biotechnology and Food Science, Faculty of Applied Sciences, Durban University of Technology, Durban, South Africa.
Fatai Oladunni BalogunDepartment of Biotechnology and Food Science, Faculty of Applied Sciences, Durban University of Technology, Durban, South Africa.ORCID https://orcid.org/0000-0002-1125-0107
Saheed SabiuDepartment of Biotechnology and Food Science, Faculty of Applied Sciences, Durban University of Technology, Durban, South Africa.ORCID https://orcid.org/0000-0001-7209-9220

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malaria is a devastating disease, and its management is only achieved through chemotherapy. However, resistance to available medication is still a challenge; therefore, there is an urgent need for the discovery and development of therapeutics with a novel mechanism of action to counter the resistance scourge consistent with the currently available antimalarials. Recently, plasmepsin V was validated as a therapeutic target for the treatment of malaria. The pepsin-like aspartic protease anchored in the endoplasmic reticulum is responsible for the trafficking of parasite-derived proteins to the erythrocytic surface of the host cells. In this study, a small library of compounds was preliminarily screened

Indexed as

KaempferolsPlasmodium falciparumAspartic Acid EndopeptidasesNaphthoquinonesPepstatinsQuercetinAspartic Acid EndopeptidasesKaempferolsNaphthoquinonesPepstatinsplasmepsinQuercetinshikonin

Identifiers

PMID37388365
PMCPMC10307063

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.